×
Importance of pre-operative ultrasound examination and pathological tumour evaluation i...
https://doi.org/10.1016/j.ejogrb.2020.12.029
European Journal of Obstetrics, Gynecology, and Reproduct... Sobočan M, Ogrizek AM et. al.

Jan 1st, 2021 - Endometrial cancer (EC) is the most common gynaecological malignancy in developed countries. Early and accurate diagnostic assessment is crucial for appropriate treatment planning. Information obtained by pre-operative imaging with transvaginal ultrasound (TVUS) and histological endometrial biopsy assessment is often the cornerstone for further management planning. This study aimed to analyse t...

Impact of restaging lymphadenectomy after sentinel node biopsy on endometrial cancer.
https://doi.org/10.1016/j.ejogrb.2020.12.028
European Journal of Obstetrics, Gynecology, and Reproduct... Gorostidi M, Ruiz R et. al.

Jan 1st, 2021 - Approximately 10 % of patients with an intra-operative diagnosis of low-risk endometrial cancer (EC) will be upstaged after a definitive histological evaluation of hysterectomy and bilateral adnexectomy samples. This study aimed to explore the results associated with the performance of pelvic and para-aortic lymphadenectomy for restaging after upstaging/upgrading these patients, and to compare ...

Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212741
Clinical and Translational Science; Yin X, Zhao Z et. al.

Jan 1st, 2021 - The efficacy of agents targeting epidermal growth factor receptor (EGFR) in patients with various cancers was well elucidated. However, the safety profile of EGFR tyrosine kinase inhibitors (EGFR-TKIs) has not been systematically investigated. This meta-analysis aimed to evaluate the safety profile of EGFR-TKIs in patients with cancer. A systematic search of PubMed, EMBASE, Cochrane Library dat...

Dr. Price on the Rationale for Sotorasib in Advanced Gastrointestinal Cancers
https://www.onclive.com/view/dr-price-on-the-rationale-for-sotorasib-in-advanced-gastrointestinal-cancers

Dec 31st, 2020 - Timothy Price, MBBS, DHthSc, FRACP, senior consultant medical oncologist and director of Medical Oncology and Clinical Cancer Research at The Queen Elizabeth Hospital in Adelaide, discusses the rationale to evaluate sotorasib (AMG 510) in gastrointestinal (GI) cancers. Findings from the phase 2 CodeBreak 100 trial (NCT03600883), which were presented during the ESMO Asia Virtual Congress 2020...

Surufatinib Approved in China for Non-Pancreatic Neuroendocrine Tumors
https://www.onclive.com/view/surufatinib-approved-in-china-for-non-pancreatic-neuroendocrine-tumors

Dec 30th, 2020 - The China National Medical Products Administration has approved surufatinib (Sulanda) for the treatment of patients with non-pancreatic neuroendocrine tumors.1 The regulatory decision was based on data from the phase 3 SANET-ep trial (NCT02589821), which showed that the agent led to a significant improvement in progression-free survival (PFS) vs placebo; the agent was also found to have a favo...

SAR439859 Achieves On-Target Activity in Metastatic ER+ Breast Cancer
https://www.onclive.com/view/sar439859-achieves-on-target-activity-in-metastatic-er-breast-cancer

Dec 29th, 2020 - The investigational selective estrogen receptor degrader (SERD) SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms, according to phase 1/2 results of a biomarker analysis. Results of the analysis, which was presented during the 2020 ES...

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, trea...
https://doi.org/10.1016/j.annonc.2020.12.007
Annals of Oncology : Official Journal of the European Soc... Bossi P, Chan AT et. al.

Dec 29th, 2020 - Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2020|Bossi P,Chan AT,Licitra L,Trama A,Orlandi E,|diagnosis,epidemiology,therapy,diagnosis,epidemiology,therapy,

Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling.
https://doi.org/10.1016/j.annonc.2020.12.010
Annals of Oncology : Official Journal of the European Soc... Ococks E, Frankell AM et. al.

Dec 29th, 2020 - The incidence of esophageal adenocarcinoma (EAC) is rapidly rising and has a 5-year survival rate of <20%. Beyond TNM (tumor-node-metastasis) staging, no reliable risk stratification tools exist and no large-scale studies have profiled circulating tumor DNA (ctDNA) at relapse in EAC. Here we analyze the prognostic potential of ctDNA dynamics in EAC, taking into account clonal hematopoiesis with...

Diagnosis and Management of Gestational Trophoblastic Disease: A Comparative Review of ...
https://doi.org/10.1097/OGX.0000000000000848
Obstetrical & Gynecological Survey; Tsakiridis I, Giouleka S et. al.

Dec 29th, 2020 - Gestational trophoblastic disease (GTD) is associated with increased mortality and morbidity in women of reproductive age, if managed in a suboptimal way, left untreated, or diagnosed after the development of extensive metastases. The aims of this study were to review and compare the recommendations from published guidelines on these tumors of placental origin. A descriptive review of guideline...

Prognostic validation and clinical implications of the EANO ESMO classification of lept...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301235
Neuro-oncology Le Rhun E, Devos P et. al.

Dec 29th, 2020 - The EANO ESMO guidelines have proposed a classification of leptomeningeal metastases (LM) from solid cancers based on clinical, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytology presentation. MRI patterns are classified as linear, nodular, both, or neither. Type I LM is defined by positive CSF cytology (confirmed LM) whereas type II LM is defined by typical clinical and M...

FDA Grants Priority Review to Frontline Lorlatinib for ALK+ Metastatic NSCLC
https://www.onclive.com/view/fda-grants-priority-review-to-frontline-lorlatinib-for-alk-metastatic-nsclc

Dec 28th, 2020 - The FDA has granted priority review to a supplemental new drug application (sNDA) for lorlatinib (Lorbrena) for use as a frontline treatment in patients with ALK-positive metastatic non–small cell lung cancer (NSCLC).1 The application is based on findings from an interim analysis of the pivotal phase 3 CROWN trial (NCT03052608) in which the third-generation ALK TKI elicited higher overall and ...

ESMO Asia 2020: First-Line Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma
https://ascopost.com/issues/december-25-2020/first-line-sintilimab-plus-bevacizumab-biosimilar-for-advanced-hepatocellular-carcinoma/

Dec 25th, 2020 - Sintilimab, an anti–PD-1 antibody, in combination with a bevacizumab biosimilar as first-line therapy significantly improved survival compared to sorafenib in patients with advanced hepatocellular carcinoma, according to findings presented by Ren et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA2). ORIENT-32 Researchers presented data from the phase III efficacy portion of the randomiz...

ESMO Asia 2020: Baseline Characteristics of Asian Patients Enrolled in the monarchE Trial
https://ascopost.com/issues/december-25-2020/baseline-characteristics-of-asian-patients-enrolled-in-the-monarche-trial/

Dec 25th, 2020 - A comparison of baseline characteristics in patients with hormone receptor (HR)-positive, HER2-negative early breast cancer revealed that a higher proportion of patients enrolled from Asia had risk factors for disease recurrence than those enrolled from non-Asian countries, reported Jiang et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA1). Researchers presented the baseline data of pa...

ESMO Asia 2020: Early Detection and Localization of Cancer Using a Blood-Based Assay
https://ascopost.com/issues/december-25-2020/early-detection-and-localization-of-cancer-using-a-blood-based-assay/

Dec 25th, 2020 - The ELSA-seq assay was able to detect diverse cancer types at early stages with high specificity and was able to provide information regarding the tissue of origin, according to findings presented by Gao et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA3). Qiang Gao, MD, PhD, of the Liver Cancer Institute, Zhongshan Hospital, Fudan University in Shanghai, discussed the underlying ratio...

Phase II Study of Combination Immunotherapy for Advanced Nasopharyngeal Cancer
https://ascopost.com/issues/december-25-2020/phase-ii-study-of-combination-immunotherapy-for-advanced-nasopharyngeal-cancer/

Dec 25th, 2020 - Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated efficacy and safety findings from a phase II study presented by Kao et al at ESMO Asia Virtual Congress 2020 (Abstract 266O). According to the presenting authors, nasopharyngeal carcinoma shows T-regulatory cell infiltration ...

Phase II Study Investigates Efficacy of Anlotinib in Radioiodine-Refractory Differentiated Thyroid Cancer
https://ascopost.com/issues/december-25-2020/phase-ii-study-investigates-efficacy-of-anlotinib-in-radioiodine-refractory-differentiated-thyroid-cancer/

Dec 25th, 2020 - Patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma demonstrated a statistically significant progression-free survival benefit when treated with anlotinib, a novel tyrosine kinase inhibitor, vs placebo, as well as higher response rates, according to findings from a phase II study presented by Chi et al at the ESMO Asia Virtual Congress 2020 (Abst...

Phase III GEMSTONE-302 Trial Finds CS1001 Plus Platinum Chemotherapy Prolongs Progression-Free Survival in NSCLC
https://ascopost.com/issues/december-25-2020/phase-iii-gemstone-302-trial-finds-cs1001-plus-platinum-chemotherapy-prolongs-progression-free-survival-in-nsclc/

Dec 25th, 2020 - The addition of CS1001, an anti–PD-L1 monoclonal antibody, to platinum-based chemotherapy significantly prolonged progression-free survival vs chemotherapy in treatment-naive patients with advanced non–small cell lung cancer (NSCLC), according to phase III findings presented by Zhou et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA4). Researchers presented findings from a preplanned an...

Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab
https://ascopost.com/issues/december-25-2020/subgroup-analysis-of-japanese-patients-with-ovarian-cancer-treated-with-maintenance-olaparibbevacizumab/

Dec 25th, 2020 - Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free survival benefit over bevacizumab alone in a Japanese subset of patients with advanced ovarian cancer (...

Matching Novel Targets to Treatment Generates Excitement in TNBC
https://www.onclive.com/view/matching-novel-targets-to-treatment-generates-excitement-in-tnbc

Dec 24th, 2020 - Important targets have emerged in triple-negative breast cancer (TNBC) in recent years, according to Neelima Vidula, MD, and innovative therapeutic interventions, such as PARP inhibitors and antibody-drug conjugates (ADCs), have been developed to match them. As such, germline genetic testing has become an important staple of care. It’s very important for patients with advanced TNBC to undergo ...

Despite Efforts Made With Immunotherapy in Metastatic Urothelial Cancer, Chemotherapy Remains King in Frontline
https://www.onclive.com/view/despite-efforts-made-with-immunotherapy-in-metastatic-urothelial-cancer-chemotherapy-remains-king-in-frontline

Dec 24th, 2020 - Platinum-based chemotherapy continues to serve as the standard of care for the frontline treatment of patients with metastatic urothelial cancer, despite many efforts made to examine immunotherapy and chemoimmunotherapy in this setting, according to Shilpa Gupta, MD. However, for those who are ineligible for cisplatin, immunotherapy options are available. The only time single-agent immunothera...